ZD1839

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

28 competitors in Neoadjuvant

#DrugCompanyPhaseTrials

1

Taxol

Teva

Approved

62

Opdivo

Bristol-Myers Squibb

Phase 2

63

Keytruda

Merck & Co.

Phase 2

24

Ellence

Pfizer

Phase 2

15

Nubeqa

Bayer

Phase 2

16

Tagrisso

AstraZeneca

Phase 2

17

Verzenio

Eli Lilly

Phase 2

18

Lenvima

Eisai

Phase 2

19

Adriamycin

Pfizer

Phase 2

110

Libtayo

Regeneron

Phase 2

1Show 18 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer5 trials

Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00193336·60 enrolled

ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 1·NCT00328562·13 enrolled

Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00068653·27 enrolled

Show 2 more trials

Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00231465·44 enrolled

Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer

Withdrawn·AstraZeneca·Phase 3·NCT00090675

Lung Cancer2 trials

An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck

Approved for marketing·AstraZeneca··NCT00684385

Iressa/Docetaxel in Non-Small-Cell Lung Cancer

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT00048087

Gastroesophageal Junction Cancer1 trial

Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer

Completed·—·Phase 2·NCT00268346·58 enrolled

Metastatic Urothelial Cancer1 trial

Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00479089·50 enrolled

Breast Cancer1 trial

A Feasibility Study With Iressa in Resistant Cytokeratin-Positive Tumor Cells Circulating in the Blood of Women With Breast Cancer

Completed·—·Phase 2·NCT00428896·24 enrolled

14 more indications

Efficacy1 trial

This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.

Completed·Sanofi·Phase 2·NCT00059722·160 enrolled

Ovarian Carcinoma1 trial

A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy

Completed·AAGO Study Group·Phase 2·NCT00189358

Advanced Cancer1 trial

Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer

Completed·AstraZeneca·Phase 1·NCT00502060·65 enrolled

Prostate Cancer1 trial

Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer

Completed·—·Phase 2·NCT00242918·29 enrolled

Colorectal Cancer1 trial

Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer

Completed·UUniversity of Chicago·Phase 1/2·NCT00026299·14 enrolled

Head Neck Cancer1 trial

ZD1839 (IRESSA™) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck Cancer

Completed·AstraZeneca·Phase 2·NCT00242762·36 enrolled

Head and Neck Cancer1 trial

Safety Trial of IRESSA, Cisplatin and Radiation Therapy for Patients With Head and Neck Cancer

Terminated·WWeill Medical College of Cornell University·Phase 1/2·NCT00195078·29 enrolled

Germ Cell Tumor1 trial

A Phase II Study of Iressa in Patients With Chemo Refractory Germ Cell Tumors Expressing EGFR

Terminated·IIndiana University School of Medicine·Phase 2·NCT00198159·21 enrolled

Treatment1 trial

Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment

Approved for marketing·AstraZeneca··NCT00683306

Squamous Cell Carcinoma1 trial

A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma

Completed·UUniversity of Chicago·Phase 2·NCT01185158·46 enrolled

ESS1 trial

Iressa Expanded Access Program (EAP)

Completed·AstraZeneca·Phase 3·NCT00034879

Cancer of the Head and Neck1 trial

ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck

Completed·UUniversity of Chicago·Phase 2·NCT00015964·51 enrolled

Neoadjuvant1 trial

Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·N/A·NCT00104728·42 enrolled

Malignant Mesothelioma1 trial

An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma

Completed·AstraZeneca·Phase 2·NCT00787410·23 enrolled

Details

Drug Info

Related News